Bachem Holding AG logo

Bachem Holding AG (BANB)

Market Closed
10 Aug, 15:20
SIX SIX
74. 50
CHF
+0.85
+1.1541%
CHF
- Market Cap
- P/E Ratio
3.93% Div Yield
81,023 Volume
- Eps
73.65 CHF
Previous Close
Add Transaction
Day Range
72.05 74.95
Year Range
48.52 83.25
Want to track BANB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

BANB closed yesterday higher at 74.5 CHF, an increase of 1.1541% from Friday's close, completing a monthly decrease of -1.9737% or -1.5 CHF. Over the past 12 months, BANB stock gained 25%.
BANB pays dividends to its shareholders, with the most recent payment made on May 06, 2026. The next estimated payment will be in In 8 months on May 06, 2027 for a total of 0.9 CHF.
The last earnings report, released on Mar 12, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Bachem Holding AG has completed 3 stock splits, with the recent split occurring on May 05, 2022.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on SIX (CHF).

BANB Chart

Bachem Holding AG (BANB) FAQ

What is the stock price today?

The current price is 74.50 CHF.

On which exchange is it traded?

Bachem Holding AG is listed on SIX.

What is its stock symbol?

The ticker symbol is BANB.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 3.93%.

What is its market cap?

As of today, no market cap data is available.

Has Bachem Holding AG ever had a stock split?

Bachem Holding AG had 3 splits and the recent split was on May 05, 2022.

Bachem Holding AG Profile

Chemicals Industry
Materials Sector
Anne-Kathrin Stoller CEO
SIX Exchange
CH1176493729 ISIN
CH Country
2,207 Employees
4 May 2026 Last Dividend
25 Apr 2019 Last Split
- IPO Date

Overview

Bachem Holding AG is a prestigious entity entrenched in the pharmaceutical and biotechnology sectors globally, offering an extensive array of products and services for research, clinical development, and commercial applications. Founded in 1971 and headquartered in Bubendorf, Switzerland, Bachem has established itself as a vital partner to many companies within these industries. The corporation specializes in supporting the development, production, and regulatory compliance of peptide active pharmaceutical ingredients, alongside providing a range of services that encompass project management, quality regulation, and comprehensive supply chain solutions.

Products and Services

Under the extensive portfolio of Bachem Holding AG, the offerings can be categorized into specific products and a suite of pertinent services designed to meet the comprehensive needs of its clientele across the pharmaceutical and biotechnology landscapes. These include:

  • Peptide and Oligonucleotide New Chemical Entities (NCEs): Bachem excels in the development and production of peptide and oligonucleotide active pharmaceutical ingredients (APIs), which are critical for new drug development processes. These entities are designed to meet stringent quality and regulatory standards essential for clinical development.
  • Commercial NCEs and Generics: In addition to developing NCEs for newer treatments, Bachem offers a range of commercial NCEs and generic APIs. These products are foundational in creating accessible and effective pharmaceutical treatments, ensuring a broader reach of medication to markets worldwide.
  • Project Management Services: With a strategic focus on delivering optimal results, Bachem provides comprehensive project management services. This encompasses all stages of product development from concept to market, ensuring projects are completed efficiently and effectively.
  • Quality and Regulatory Services: Understanding the critical importance of compliance and quality, Bachem offers dedicated support in navigating the complex landscape of regulatory requirements. This ensures all products are compliant with international standards, safeguarding end-user safety and efficacy of treatments.
  • Analytical Services: Analytical services are essential in verifying the purity, potency, and quality of pharmaceutical ingredients. Bachem supports its clients with advanced analytical methodologies and technologies, reinforcing the integrity of their products.
  • Good Manufacturing Practice (GMP) Production: Adherence to GMP is paramount in the pharmaceutical industry. Bachem’s GMP production services ensure that products are consistently produced and controlled according to quality standards, guaranteeing they are suitable for their intended use.
  • Research Grade Production: For early-stage research and development projects, Bachem provides research-grade production services. These offerings facilitate the exploration and testing of new compounds with the potential to advance scientific understandings and lead to novel treatments.
  • Supply and Vertical Integration Services: To streamline the supply chain and enhance efficiency, Bachem offers supply and vertical integration services. This comprehensive support helps in managing the complexities associated with the sourcing and production of pharmaceutical ingredients.

Contact Information

Address: Hauptstrasse 144
Phone: 41 58 595 2021